Crossmark

Adjunctive Therapies in Parkinson’s Disease: How to Choose the Best Treatment Strategy Approach

Crossref DOI link: https://doi.org/10.1007/s40266-018-0599-2

Published Online: 2018-10-15

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fabbri, Margherita

Rosa, Mario M.

Ferreira, Joaquim J.
License Information

Text and Data Mining valid from 2018-10-15
More Information

Article History

First Online: 15 October 2018

Compliance with Ethical Standards

:

: No specific funding was received for this work.

: Dr. Margherita Fabbri reports grants from AbbVie. Prof. Mario Miguel Rosa reports no conflict of interests and no additional disclosures. Prof. Joaquim J. Ferreira reports consultancies for Ipsen, GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, BIAL, Merck-Serono and Merz. He has also received grants from GlaxoSmithKline, Grunenthal, Teva and Fundação MSD.